Business Context and Reporting Period
This Form 8-K Current Report was filed by Catalyst Biosciences, Inc. (trading symbol: CBIO) on January 26, 2021. The registrant is a Delaware corporation headquartered in South San Francisco, California. The filing reports the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Underwriting agreement for the sale of common stock.
- Shares Issued: 8,700,000 shares of common stock.
- Offering Price: $5.75 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 1,305,000 shares.
- Estimated Net Proceeds: Approximately $50 million (after underwriting discounts, commissions, and estimated expenses, assuming no exercise of the over-allotment option).
- Use of Proceeds: General corporate purposes, including research, development, and manufacturing for hemophilia and complement programs (specifically MarzAA and CB 4332), capital expenditures, SG&A costs, facilities expansion, and working capital.
- Expected Closing Date: January 29, 2021.
Material Changes
The filing does not provide comparative financial data (revenue, profit, cash flow, or margins) as it is a current report regarding a specific corporate event rather than a periodic financial statement. The primary material change is the execution of the underwriting agreement to raise capital, which will significantly increase the company's cash liquidity upon closing.
Outlook, Risks, and Management Commentary
Management intends to utilize the raised capital to advance specific clinical programs, including MarzAA (FVIIa) for hemophilia and CB 4332 (enhanced complement Factor I). The offering is subject to customary closing conditions. The filing references a press release issued on January 27, 2021, confirming the pricing of the offering. No specific risks or contingencies beyond standard underwriting terms (market standoff, termination provisions) are detailed in the text of this summary.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the $50 million figure is an estimate excluding the over-allotment option.
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 1,305,000 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific lock-up periods and indemnification obligations.
- Monitor subsequent filings for the actual allocation of funds to the specified research and development programs.